scholarly journals Universal Nerve Conduction Screening in Type 1 Diabetes—Are We There Yet?

2022 ◽  
Author(s):  
Anurag Bajpai
Keyword(s):  
Type 1 Diabetes ◽  
Nerve Conduction

Point-of-Care Nerve Conduction for the Identification of Neuropathy in Older Adults with Type 1 Diabetes

2017 ◽  
Vol 41 (5) ◽  
pp. S63
Author(s):  
Daniel Scarr ◽  
Leif E. Lovblom ◽  
Nancy Cardinez ◽  
Andrej Orszag ◽  
Mohammed A. Farooqi ◽  
...  
Keyword(s):  
Older Adults ◽  
Type 1 Diabetes ◽  
Nerve Conduction ◽  
Point Of Care

scholarly journals Hypertension Contributes to Neuropathy in Patients With Type 1 Diabetes

2019 ◽  
Vol 32 (8) ◽  
pp. 796-803 ◽  
Author(s):  
Georgios Ponirakis ◽  
Ioannis N Petropoulos ◽  
Uazman Alam ◽  
Maryam Ferdousi ◽  
Omar Asghar ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 1 Diabetes ◽  
Nerve Conduction ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Fiber Density ◽  
Converting Enzyme Inhibitors ◽  
Perception Threshold ◽  
Pressure Lowering

Abstract BACKGROUND Diabetic peripheral neuropathy (DPN) can lead to foot ulceration and amputation. There are currently no disease-modifying therapies for DPN. The aim of this study was to determine if hypertension contributes to DPN in patients with type 1 diabetes mellitus (T1DM). METHODS Subjects with T1DM (n = 70) and controls (n = 78) underwent a comprehensive assessment of DPN. RESULTS Hypertension was present in 40 of 70 T1DM subjects and 20 of 78 controls. Hypertension was associated with abnormal nerve conduction parameters (P = 0.03 to <0.001), increased vibration perception threshold (P = 0.01) and reduced corneal nerve fiber density and length (P = 0.02) in subjects with T1DM. However, after adjusting for confounding factors only tibial compound motor action potential and nerve conduction velocity were associated with hypertension (P = 0.03) and systolic blood pressure (P < 0.01 to <0.0001). Hypertension had no effect on neuropathy in subjects without diabetes. CONCLUSIONS This study shows that hypertension is associated with impaired nerve conduction in T1DM. It supports previous small trials showing that angiotensin-converting enzyme inhibitors improve nerve conduction and advocates the need for larger clinical trials with blood pressure lowering agents in DPN.

scholarly journals Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

PLoS ONE ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. e0196647 ◽  
Author(s):  
Daniel Scarr ◽  
Leif E. Lovblom ◽  
Nancy Cardinez ◽  
Andrej Orszag ◽  
Mohammed A. Farooqi ◽  
...  
Keyword(s):  
Older Adults ◽  
Type 1 Diabetes ◽  
Nerve Conduction ◽  
Point Of Care ◽  
Canadian Study

scholarly journals Effect of omega-3 supplementation on neuropathy in type 1 diabetes

Neurology ◽  
2017 ◽  
Vol 88 (24) ◽  
pp. 2294-2301 ◽  
Author(s):  
Evan J.H. Lewis ◽  
Bruce A. Perkins ◽  
Leif E. Lovblom ◽  
Richard P. Bazinet ◽  
Thomas M.S. Wolever ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Nerve Conduction ◽  
Sensory Function ◽  
Omega 3 ◽  
Open Label ◽  
Pufa Supplementation ◽  
Corneal Confocal Microscopy ◽  
Seal Oil

Objective:To test the hypothesis that 12 months of seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation will stop the known progression of diabetic sensorimotor polyneuropathy (DSP) in type 1 diabetes mellitus (T1DM).Methods:Individuals with T1DM and evidence of DSP as determined by a Toronto Clinical Neuropathy Score ≥1 were recruited to participate in a single-arm, open-label trial of seal oil ω-3 PUFA supplementation (10 mL·d−1; 750 mg eicosapentaenoic acid, 560 mg docosapentaenoic acid, and 1,020 mg docosahexaenoic acid) for 1 year. The primary outcome was the 1-year change in corneal nerve fiber length (CNFL) measured by in vivo corneal confocal microscopy, with sensory and nerve conduction measures as secondary outcomes.Results:Forty participants (53% female), aged 48 ± 14 years, body mass index 28.1 ± 5.8 with diabetes duration of 27 ± 18 years, were enrolled. At baseline, 23 participants had clinical DSP and 17 did not. Baseline CNFL was 8.3 ± 2.9 mm/mm2 and increased 29% to 10.1 ± 3.7 mm/mm2 (p = 0.002) after 12 months of supplementation. There was no change in nerve conduction or sensory function.Conclusions:Twelve months of ω-3 supplementation was associated with increase in CNFL in T1DM.ClinicalTrials.govidentifier:NCT02034266.Classification of evidence:This study provides Class IV evidence that for patients with T1DM and evidence of DSP, 12 months of seal oil omega-3 supplementation increases CNFL.

scholarly journals Automated Measurement of Sural Nerve Conduction is a Useful Screening Tool for Peripheral Neuropathy in Type 1 Diabetes Mellitus

2019 ◽  
Vol 15 (1) ◽  
pp. 58-59
Author(s):  
Nikolaos Papanas ◽  
Kalliopi Pafili ◽  
Maria Demetriou ◽  
Georgia Chatzikosma ◽  
Stella Papachristou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Peripheral Neuropathy ◽  
Type 1 Diabetes Mellitus ◽  
Nerve Conduction ◽  
Sural Nerve ◽  
Screening Tool ◽  
Automated Measurement

TP4.5 Cognitive impact, evoked potentials and nerve conduction in patients with type 1 diabetes

2006 ◽  
Vol 117 ◽  
pp. 120
Author(s):  
T. Brismar ◽  
L. Maurex ◽  
G. Cooray ◽  
P. Lindström ◽  
L. Juntti-Berggren ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Evoked Potentials ◽  
Nerve Conduction
Sign in / Sign up

Export Citation Format

Share Document